Bank of New York Mellon
ALNA

Bank of New York Mellon’s Allena Pharmaceuticals ALNA Stock Holding History

Bank of New York Mellon’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34,026
Closed -$44K – 4580
2021
Q2 		$44K Sell
34,026
-5,160
-13% -$6.25K ﹤0.01% 4340
2021
Q1 		$54K Buy
+39,186
New +$65.3K ﹤0.01% 4251
2019
Q4 		– Sell
-19,096
Closed -$75K – 4257
2019
Q3 		$75K Sell
19,096
-4,623
-19% -$19.8K ﹤0.01% 4067
2019
Q2 		$96K Sell
23,719
-7,667
-24% -$41.9K ﹤0.01% 4037
2019
Q1 		$221K Buy
31,386
+1,865
+6% +$13.5K ﹤0.01% 3854
2018
Q4 		$161K Sell
29,521
-2,315
-7% -$20K ﹤0.01% 3890
2018
Q3 		$342K Buy
31,836
+699
+2% +$7.68K ﹤0.01% 3787
2018
Q2 		$406K Buy
31,137
+20,954
+206% +$302K ﹤0.01% 3719
2018
Q1 		$113K Buy
10,183
+1
+0% +$8 ﹤0.01% 4043
2017
Q4 		$102K Buy
+10,182
New +$125K ﹤0.01% 4096

Other funds holding ALNA

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of New York Mellon's ALNA Position: Q3 2021 in Review

Bank of New York Mellon sold out of Allena Pharmaceuticals (ALNA) in Q3 2021, closing a stake of 34,026 shares — an estimated $44K sold.

Bank of New York Mellon first reported a position in ALNA in Q4 2017 and held it in 10 quarters. The position peaked at $406K in Q2 2018. 36 funds tracked by Wall St. Rank hold ALNA as of Q3 2021.

  • Bank of New York Mellon reported no remaining Allena Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 34,026 Allena Pharmaceuticals shares in Q3 2021, an estimated $44K.
  • Bank of New York Mellon first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 10 quarters.
  • Bank of New York Mellon's Allena Pharmaceuticals position peaked at $406K in Q2 2018.
  • 36 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2021.

Based on Bank of New York Mellon's 13F filing for Q3 2021, filed 12 Nov 2021.